ONDCP Funds Research to Support Evidence-Based State Drug Policies and Laws
Initiative will advise states on expanding harm reduction, as well as ensuring equity in drug treatment and enforcement
WASHINGTON, D.C. – As part of efforts to address addiction and the overdose epidemic, the Office of National Drug Control Policy today announced $2.5 million to support the establishment of state-level model legislation that advances efforts to expand access to harm reduction services, as well as promote equity in access to treatment and drug enforcement efforts for underserved communities. The Legislative Analysis and Public Policy Association (LAPPA) is the cooperative agreement award recipient through the Office of National Drug Control Policy’s (ONDCP) Model Acts Program.
Specifically, this funding will support the drafting of evidence-based model legislation on topics including:
- Ensuring access to harm reduction services such as syringe service programs;
- Equitable enforcement of drug laws and access to treatment;
- Stigma reduction for substance use disorder;
- Strategies to address fentanyl, cocaine and methamphetamine trafficking and use.
Previously through this initiative, states have introduced the Model Fatality Reviews Act, a LAPPA model law that would establish county-level multidisciplinary overdose fatality review that can be used to identify and respond to overdose deaths; and the Model Overdose Mapping (ODMAP) and Response Act, a LAPPA model law that would establish a system to track overdose incident reporting and improve public health and public safety responses.
BACKGROUND ON ADMINISTRATION ACTIONS ON ADDICTION AND OVERDOSE
In its first-year drug policy priorities, the Biden-Harris Administration outlined a strategy that includes expanding access to evidence-based prevention, treatment, harm reduction, and recovery support services, as well reducing the supply of illicit drugs. Since January, the Office of National Drug Control Policy has worked with other agencies across the government to advance President Biden’s drug policy priorities. Among the actions taken in the first six months of the Biden-Harris Administration are:
- The American Rescue Plan invested nearly $4 billion to allow the Department of Health and Human Services’ (HHS) Substance Abuse and Mental Health Services Administration (SAMHSA) and Health Resources and Services Administration to expand access to vital mental health and substance use disorder services. The funding also included $30 million in supports for harm reduction services—a historic amount that will enhance interventions like syringe services programs.
- HHS released the Practice Guidelines for the Administration of Buprenorphine for Treating Opioid Use Disorder, which exempt eligible health care providers from Federal certification requirements related to training, counseling and other ancillary services that are part of the process for obtaining a waiver to treat up to 30 patients with buprenorphine. This action expands access to evidence-based treatment by removing a critical barrier to buprenorphine prescribing.
- The Drug Enforcement Administration (DEA) lifted a decade-long moratorium on opioid treatment programs that want to include a mobile component. This rule change will help provide treatment to rural and other underserved communities, including incarcerated individuals.
- CDC and SAMHSA announced that Federal funding may now be used to purchase fentanyl test strips in an effort to help curb the dramatic spike in drug overdose deaths.
- ONDCP designated six new counties as part of its High Intensity Drug Trafficking Areas (HIDTA) program. These counties, located in states like California, Illinois, Kentucky, and Pennsylvania, will receive support for regional law enforcement efforts to disrupt and dismantle drug trafficking organizations.
- ONDCP provided funding for the nationwide expansion of the HIDTA Overdose Response Strategy to all 50 states, Puerto Rico, the U.S. Virgin Islands, and the District of Columbia. The Strategy brings together drug intelligence officers and public health analysts at the local and regional level to share information and develop evidence-based intervention and support services that reduce overdoses.
In addition to these actions, the President’s FY22 budget request calls for $10.7 billion to support research, prevention, treatment, harm reduction, and recovery support services, with targeted investments to meet the needs of populations at greatest risk for overdose and substance use disorder.
The FY22 budget request also includes significant investments in reducing the supply of illicit substances. In particular, it includes important increases in interdiction efforts, which include air and maritime activities to seize drugs in transit and deter access to routes, enhancements of source nations’ ability to interdict drugs, and efforts along the United States border to interdict the flow of drugs. The FY22 request also continues to support efforts to strengthen source country programs that address drug trafficking and corruption, strengthen the rule of law and anti-corruption activities, promote human rights, and support development programs.